A Trial on the Efficacy, Safety and Immunogenicity of Live-Attenuated Influenza Vaccine (LAIV)
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase Ⅲ Trial on the Efficacy, Safety and Immunogenicity of Live-Attenuated Influenza Vaccine (LAIV)
Sponsor: Baoding Municipal Center for Disease Control and Prevention, Hebei, P.R.China
Listed as NCT02964065, this PHASE3 trial focuses on Influenza and remains completed. Sponsored by Baoding Municipal Center for Disease Control and Prevention, Hebei, P.R.China, it has been updated 9 times since 2016, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.
Status Flow
Change History
9 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Oct 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Oct 2021 [monthly]
Completed PHASE3
▶ Show 4 earlier versions
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE3
-
Oct 2017 — Jun 2018 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
-
Feb 2017 — Oct 2017 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE3
First recorded
Nov 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Baoding Municipal Center for Disease Control and Prevention, Hebei, P.R.China
- Changchun BCHT Biotechnology Co.
- Department of Medical Statistics, Fourth Military Medical University
- Maoming Municipal Center for Disease Control and Prevention, Guangdong, P.R.China
- National Institutes for Food and Drug Control, China
- Simoon Record Pharma Information Consulting Co., Ltd.
- Zhejiang Provincial Center for Disease Control and Prevention
For direct contact, visit the study record on ClinicalTrials.gov .